Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Nov

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

FDA Approves Expanded Indication for Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC

Broad-Based Genomic Sequencing Associated With Survival Benefit Over Focused Testing for Advanced NSCLC

Surgical Resection Associated With Lower Mortality Than SABR in Early-Stage NSCLC

Clinical Trial Participation Among Patients With Advanced Cancer Driven by Structural Factors at Physician and Practice Levels

Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer